Find a Financial Advisor for Pharmaceutical Executives: Q&A Insights from the Experts

Unvested Equity and Deferred Compensation Elections Can Make Leaving an Employer Very Costly Without a Plan

Pharmaceutical executives changing jobs should map every unvested grant and its next vesting date before resigning, as waiting a short time can preserve meaningful value. Deferred compensation elections and pension payout choices may also lock in terms years in advance, making pre-resignation review essential.

The First Years of Retirement Can Be a Pharma Executive’s Highest-Income Years, Creating Unexpected Tax Exposure

Final bonuses, continued equity vesting, and deferred compensation payouts can combine to produce a larger tax bill than expected at the start of retirement. Planning the income sequence several years in advance—including identifying lower-income years suitable for Roth conversions—helps avoid that surprise.

Even Experienced Pharma Executives Often Misunderstand How Their Stock Options and RSUs Actually Work

A case described in the Q&A shows how a senior executive discovered that vested RSUs would be withheld for taxes and most stock options had little value due to their exercise price—only after a job change and acquisition. Having plan documents available is not enough; understanding how the terms affect decisions requires dedicated review time.

A financial planning challenge particularly common among pharmaceutical executives is managing complex compensation while navigating frequent company reorganizations. Their compensation often includes restricted stock units (RSUs), performance stock units (PSUs), stock options, and employee stock purchase plans (ESPPs). The challenge is understanding how these pieces fit together and how a change in their role or employment could affect their financial plans.

We help clients organize their finances and coordinate their compensation decisions with their broader financial goals. We build a plan together so that when a reorganization happens, their role changes, or their compensation shifts, we have a foundation to work from. Then, we can evaluate their options together and help them make informed decisions.

For executives looking to better understand their benefits, we have also written guides for employees at Merck, Johnson & Johnson, Pfizer, Novartis, and Bristol Myers Squibb.

Not everyone needs an advisor, and the executives I meet are usually capable of doing a great deal themselves. The question I would ask is whether the decisions in front of you could lead to mistakes that are costly or difficult to reverse.

In pharma, several decisions can fall into that category. Deferred compensation elections may commit you to a payout schedule years in advance. Pension payout choices generally cannot be changed once payments begin. Stock options can have short exercise deadlines after you leave an employer, depending on your plan and the type of option. And a concentrated stock position that has done well for 10 years can be especially difficult to sell without a plan.

If your finances are relatively straightforward, a one-time review and good habits may be enough. If you hold equity from more than one employer, have deferred compensation, or are approaching retirement with several benefits to coordinate, ongoing advice may be more valuable. The same is true if you carry the financial decision-making responsibility in your household and want someone to help you evaluate the tradeoffs. Those are often the circumstances where an advisor can be worth it.

I start by asking, “What prompted you to reach out?” There is usually a reason: a big decision coming up, a surprise tax bill they don’t want to repeat, or something they have been meaning to organize for a while. We begin with that most pressing issue and talk through what it means for them.

Then I ask about the bigger picture. “If you could design your ideal work life or retirement, what would it look like? What would you love to include, what would you want to avoid, and what is non-negotiable?” Those answers shape the whole plan.

From there, we get into the specifics of their compensation: salary, bonuses, equity from current and past employers, deferred compensation, and pension benefits. I also ask, “Are you anticipating any changes in your role or company that could affect these benefits?”

The details matter, but they make much more sense once I understand what the person is trying to build. You can learn more about our process in How to Get Started With Align.

Before you resign, gather your equity grant agreements, stock plan summary, and deferred compensation plan document. Map out every unvested grant and its next vesting date, because sometimes waiting a few weeks can make a meaningful financial difference.

Unvested equity you would leave behind can also be part of your negotiation with the new employer, through a signing bonus or a replacement grant. Before accepting an offer, compare what you are giving up with what you are receiving, including the new vesting terms. Here is a fuller checklist for evaluating a new job offer.

Once you start the new role, track your combined 401(k) contributions, since the annual employee contribution limit generally applies across both employers. Review your options for your old 401(k), and check whether you need to set aside additional cash for taxes on equity compensation or deferred compensation payments.

For some executives, the first year or two of retirement can be among their highest-income years, with a final bonus, equity that continues to vest under their plan’s rules, and deferred compensation payouts. Without planning, this can lead to a much larger tax bill than expected at the start of retirement.

That is why we begin planning the sequence a few years in advance. We decide which accounts will fund living expenses in each phase of retirement and consider whether lower-income years that follow could be a good time for Roth conversions.

We also plan for health coverage between retirement and Medicare eligibility, typically at age 65, including how a health savings account (HSA) fits in.

Before retirement, we help clients practice living on the monthly amount their plan is designed to support. The goal is for the transition to feel like a continuation of a routine they already know.

What often surprises me is how little time even highly capable executives have to review the documents that explain their own compensation.

I worked with a marketing leader in the industry, a single woman in her 50s and the sole earner in her household. She changed employers, and her former company was acquired within a few weeks. During that transition, she learned that some of her vested restricted stock units (RSUs) would be withheld to cover taxes and that most of her stock options had little or no value because of their exercise price.

Her plan documents explained the terms, but she had not had the time or headspace to work through what they could mean for her. She was focused on her work while carrying the financial responsibility for her household.

That is something I encounter often with pharma executives. Having the information available is only the first step. Understanding how it affects your decisions is where organizing and reviewing everything ahead of time can make a meaningful difference.